共 50 条
- [31] Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter TrialJOURNAL OF THORACIC ONCOLOGY, 2022, 17 (05) : 718 - 723Ahn, Myung-JuCho, Byoung ChulOu, XiaolingWalding, AndrewDymond, Angela W.Ren, SongCantarini, MireilleJanne, Pasi A.
- [32] HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung CancerCLINICAL CANCER RESEARCH, 2022, 28 (02) : 390 - 403Yonesaka, KimioTanizak, JunkoMaenishi, OsamuHaratani, KojiKawakami, HisatoTanaka, KaoruHayashi, HidetoshiSakai, KazukoChiba, YasutakaTsuya, AsukaGoto, HirokiOtsuka, EriOkida, HiroakiKobayashi, MakiYoshimoto, RyotoFunabashi, MasanoriHashimoto, YuuriHirotani, KenjiKagari, TakashiNishio, KazutoNakagawa, Kazuhiko
- [33] A phase II study of HER3-DXD in patients (pts) with metastatic breast cancer (MBC)ANNALS OF ONCOLOGY, 2022, 33 : S220 - S220Hamilton, E. P.Bagegni, N. A.Beck, J. T.Cultrera, J. L.Dosunmu, O.Gwin, W. R.Heeke, A. L.Khoury, K.Sellami, D.Shastry, M.Sternberg, D. W.Toppmeyer, D.Wright-Browne, V. M.Yuan, Y.
- [34] HERTHENA-Lung02: A randomized Phase 3 study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR tyrosine kinase inhibitorCANCER RESEARCH, 2023, 83 (08)Halmos, BalazsYu, Helena A.Wu, Yi-LongNishio, MakotoReck, MartinSternberg, DavidEsker, StephenMok, Tony
- [35] Phase I study of SHR-A2009, a HER3-targeted ADC, in pretreated EGFR-mutated NSCLCANNALS OF ONCOLOGY, 2024, 35 : S509 - S509Zhou, Q.Wu, Y-L.Wu, L.Zhang, Y.Ni, S.Liu, A.Li, J.Lin, G.Cui, J.Yao, W.Sun, J-M.Zhang, Y.Su, H.Li, Y.Yamamoto, N.Kuboki, Y.Han, S-W.Wang, Z.Qiu, F.Yang, L.
- [36] A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC)JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Hamilton, Erika P.Dosunmu, OloladeShastry, MythiliFinney, LindseySellami, Dalila B.Sternberg, David W.Wright-Browne, VanceToppmeyer, DeborahGwin, William R.Thaddeus, J. ThaddeusCultrera, Jennifer L.Bagegni, Nusayba AliKhoury, KatiaHeeke, Arielle LuttermanYuan, Yuan
- [37] Osimertinib After Definitive CRT in Unresectable Stage III EGFR-mutated NSCLC: Safety Outcomes from the Phase 3 LAURA StudyJOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S36 - S36Kato, T.Dong, X.Takahashi, T.Soparattanapaisarn, N.Geater, S. L.Nguyen, K. V.Wang, C. L.Arriola, E.Moiseenko, F.Thompson, L.Harker, S.Grainger, E.Armenteros-Monterroso, E.Bolanos, A.Ramalingam, S.Lu, S.
- [38] Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trialJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Bartsch, RupertBatista, Marta VazBerghoff, Anna SophieFurtner, JuliaMarhold, MaximilianOberndorfer, FelicitasGarde, JavierRuiz-Borrego, ManuelGreil, RichardRaimondi, GiuliaCampolier, MartaJimenez-Cortegana, CarlosGonzalez-Alonso, PaulaSampayo-Cordero, MiguelLlombart, AntonioFuereder, ThorstenPreusser, Matthias
- [39] Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Janne, Pasi A.Yu, Helena AlexandraJohnson, Melissa LynneSteuer, Conor ErnstVigliotti, MicheleIacobucci, CorinneChen, ShuquanYu, ChanningSellami, Dalila B.
- [40] HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR TKIANNALS OF ONCOLOGY, 2022, 33 (07) : S1095 - S1095Mok, T. S. K.Wu, Y-L.Nishio, M.Reck, M.Wu, E.Sternberg, D. W.Esker, S.Yu, H. A.